logo
Plus   Neg
Share
Email

Merck Acquires AmpTec - Quick Facts

Merck announced the acquisition of AmpTec, a Germany-based, mRNA contract development and manufacturing organization. Merck said the acquisition strengthens its capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases.

"The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases," said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.

Merck said the company is continuing to invest in mRNA as a modality and will scale up this technology both at AmpTec's existing site in Hamburg and at Merck's global headquarters in Darmstadt, Germany.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT